.jpg?w=340&itok=aJ_xB8nB "IPT discussed in technical publications."){kind=icon}
In oncology, a single biomarker usually is not enough to provide useful information about a patient’s cancer or response to treatment, and the relationships between individual biomarkers can be difficult to establish or ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Lessons from the first generation of cell and gene oncology trials
ICON’s Tamie Joeckel and Brandon Fletcher take us through best practice approaches to CGT studies and discuss what the future could hold for this exciting area.
-
Ensuring better patient outcomes through decentralised & hybrid trials
ICON CEO Steve Cutler discusses how the research industry has changed in the past year, concluding that decentralised models are helping to improve patient outcomes and bring treatments to market faster (page 12).
-
Practical considerations when deploying a decentralised or hybrid clinical trial
A discussion around the key components of decentralised trials and steps of deployment.
-
‘Future protect': shoring up clinical programs against changes in standard of care
Kristen Buck and David Morse weigh in on how to avoid some recent pitfalls seen at US FDA advisory committee panels.
-
Innovation in oncology clinical trials
Dr. Brian Huber, VP Drug Development & Consulting, discusses the shift from histology-based to lesion-based trial design in precision medicine
-
.jpg?w=545&itok=QNbLGprT "IPT discussed in technical publications.")
Anatomic pathology in the digital era
Greg Cox, Director ICON Laboratory Services, shares his perspective on how integrating digital pathology into clinical trials can benefit study outcomes and data integrity.
-
Trailblazing women stress importance of diversity in pharma
Nuala Murphy, President of Clinical Research Services at ICON, discusses how increasing diversity is a key area of focus for ICON, both in terms of patient diversity and diversity in the organisation.
-
Has the pandemic enabled us to accelerate the pace of drug development?
Nuala Murphy, President Global Specialty Solutions, contributes to this Marvellous Medicine BBC4 podcast about accelerating the pace of drug development due to the pandemic.
-
The central role of Interactive Response Technology in today's clinical trials
Michelle Lynskey, Global Head of Interactive Response Technology and Clinical Supplies Management, offers her insights on the role of IRT in clinical trials (pages 42-43).
-
A trusted partner for clinical development
ICON CEO Steve Cutler chats with Newsweek, on ICON’s role in the development of much needed medicines. The interview (page 12 of PDF) is part of a special report on Ireland.
